We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+10.11%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$47.1B
AUM Growth
+$2.61B
Cap. Flow
-$501M
Cap. Flow %
-1.06%
Top 10 Hldgs %
14.43%
Holding
3,576
New
705
Increased
706
Reduced
825
Closed
988

Top Buys

Rank Stock Value
1
WMT icon
Walmart Inc
WMT
+$417M
2
META icon
Meta Platforms (Facebook)
META
+$383M
3
AMZN icon
Amazon
AMZN
+$308M
4
MSFT icon
Microsoft
MSFT
+$293M
5
GE icon
GE Aerospace
GE
+$263M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$312M
2
BAC icon
Bank of America
BAC
+$292M
3
XOM icon
ExxonMobil
XOM
+$274M
4
LULU icon
lululemon athletica
LULU
+$238M
5
QCOM icon
Qualcomm
QCOM
+$228M

Sector Composition

Rank Sector Weight
1 Healthcare 17.05%
2 Technology 14.35%
3 Consumer Discretionary 13.97%
4 Financials 9.9%
5 Industrials 6.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WE
2551
DELISTED
WeWork Inc.
WE
$11.3K ﹤0.01%
363
-904
-71% -$49.4K
DUK icon
2552
PUT
Duke Energy
DUK
$98.4B
$9.65K ﹤0.01%
100
FXB icon
2553
Invesco CurrencyShares British Pound Sterling Trust
FXB
$77.8M
$8.67K ﹤0.01%
73
-12,850
-99% -$1.5M
DMYS.WS
2554
CALL
DELISTED
dMY Technology Group, Inc. VI Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share
DMYS.WS
$2.05K ﹤0.01%
25,605
-47,828
-65% -$8.08K
VLATW
2555
CALL
DELISTED
Valor Latitude Acquisition Corp. Warrant
VLATW
$2K ﹤0.01%
49,995
ABBV icon
2556
PUT
AbbVie
ABBV
$455B
-5,100
Closed -$824K
ABCL icon
2557
AbCellera Biologics
ABCL
$1.74B
-97,600
Closed -$989K
ABG icon
2558
Asbury Automotive
ABG
$4.34B
-4,917
Closed -$881K
ABNB icon
2559
CALL
Airbnb
ABNB
$90.3B
-4,200
Closed -$359K
ABNB icon
2560
PUT
Airbnb
ABNB
$90.3B
-8,300
Closed -$710K
ACHC icon
2561
Acadia Healthcare
ACHC
$2.62B
-15,758
Closed -$1.3M
ACLS icon
2562
Axcelis
ACLS
$3.85B
-7,769
Closed -$617K
ACN icon
2563
Accenture
ACN
$99.9B
-4,787
Closed -$1.28M
ADAP
2564
DELISTED
Adaptimmune Therapeutics
ADAP
-89,171
Closed -$130K
ADI icon
2565
CALL
Analog Devices
ADI
$179B
-18,500
Closed -$3.03M
ADP icon
2566
CALL
Automatic Data Processing
ADP
$105B
-9,600
Closed -$2.29M
ADPT icon
2567
Adaptive Biotechnologies
ADPT
$3.87B
-370,471
Closed -$2.83M
ADSK icon
2568
PUT
Autodesk
ADSK
$49.6B
-17,300
Closed -$3.23M
ADTN icon
2569
Adtran
ADTN
$682M
-18,320
Closed -$330K
ADVM
2570
DELISTED
Adverum Biotechnologies
ADVM
-34,140
Closed -$198K
AENT icon
2571
Alliance Entertainment
AENT
$282M
-449,287
Closed -$4.57M
AEON icon
2572
AEON Biopharma
AEON
$11.3M
-18,418
Closed -$13.3M
AERT
2573
Aeries Technology
AERT
$36.8M
-118,974
Closed -$9.71M
AFCG
2574
AFC Gamma
AFCG
$61.1M
-18,154
Closed -$195K
AGCO icon
2575
AGCO
AGCO
$7.76B
-12,583
Closed -$1.75M

Similar funds

Marshall Wace's Q1 2023 Portfolio in Review

As of Q1 2023, Marshall Wace held 3,576 positions worth $47.1B, up 5.9% from $44.5B the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Marshall Wace's Q1 2023 filing shows 705 new, 706 increased, 825 reduced and 988 closed positions. Its largest new stake was Madrigal Pharmaceuticals: 541,764 shares worth $131M. The largest sale was Cigna, an estimated $312M.

By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Marshall Wace's largest Q1 2023 buy was Madrigal Pharmaceuticals: 541,764 shares worth $131M.
  • Marshall Wace added most to Walmart Inc in Q1 2023, an estimated $417M increase.
  • Marshall Wace's biggest Q1 2023 reduction was Cigna, cutting an estimated $312M.
  • Marshall Wace fully exited Merck in Q1 2023, selling an estimated $115M.
  • Marshall Wace's ten largest holdings make up 14% of its $47.1B portfolio in Q1 2023.
  • Marshall Wace opened 705 new positions and closed 988 in Q1 2023.
  • Marshall Wace's portfolio value rose 5.9% quarter-over-quarter to $47.1B.

Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.